Cyber Monday saleUp to 70% OFF
GLAND PHARMA LIMITEDGLAND PHARMA LIMITEDGLAND PHARMA LIMITED

GLAND PHARMA LIMITED

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

GLAND chart


Full chart

GLAND upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪283.06 B‬ INR
Dividend yield (indicated)
1.16%
Price to earnings Ratio (TTM)
40.95
Basic EPS (TTM)
42.00 INR
Net income (FY)
‪7.72 B‬ INR
Revenue (FY)
‪56.42 B‬ INR
Shares float
‪77.70 M‬
Beta (1Y)
0.24

Employees


Employees (FY)
‪4.22 K‬
Change (1Y)
−368 −8.03%
Revenue / Employee (1Y)
‪160.40 K‬ INR
Net income / Employee (1Y)
‪21.96 K‬ INR

About GLAND PHARMA LTD


Sector
Health Technology
CEO
Srinivas Sadu
Headquarters
Sangareddy
Website
glandpharma.com
Founded
1978
ISIN
INE068V01023
FIGI
BBG00Y2K95H9
Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations. It offers injectables including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, and ophthalmic solutions. The company was founded by P. V. N. Raju in 1978 and is headquartered in Sangareddy, India.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

GLAND news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of GLAND is 1,739.10 INR — it has increased by 1.22% in the past 24 hours. Watch GLAND PHARMA LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange GLAND PHARMA LIMITED stocks are traded under the ticker GLAND.
GLAND stock has fallen by −3.38% compared to the previous week, the month change is a 7.00% rise, over the last year GLAND PHARMA LIMITED has showed a −3.11% decrease.
We've gathered analysts' opinions on GLAND PHARMA LIMITED future price: according to them, GLAND price has a max estimate of 2,150.00 INR and a min estimate of 1,360.00 INR. Watch GLAND chart and read a more detailed GLAND PHARMA LIMITED stock forecast: see what analysts think of GLAND PHARMA LIMITED and suggest that you do with its stocks.
GLAND reached its all-time high on Aug 12, 2021 with the price of 4,350.00 INR, and its all-time low was 861.50 INR and was reached on May 22, 2023. View more price dynamics on GLAND chart.
See other stocks reaching their highest and lowest prices.
GLAND stock is 1.61% volatile and has beta coefficient of 0.24. Track GLAND PHARMA LIMITED stock price on the chart and check out the list of the most volatile stocks — is GLAND PHARMA LIMITED there?
Today GLAND PHARMA LIMITED has the market capitalization of ‪286.52 B‬, it has increased by 0.91% over the last week.
Yes, you can track GLAND PHARMA LIMITED financials in yearly and quarterly reports right on TradingView.
GLAND PHARMA LIMITED is going to release the next earnings report on Feb 3, 2025. Keep track of upcoming events with our Earnings Calendar.
GLAND earnings for the last quarter are 9.90 INR per share, whereas the estimation was 11.30 INR resulting in a −12.42% surprise. The estimated earnings for the next quarter are 13.00 INR per share. See more details about GLAND PHARMA LIMITED earnings.
GLAND PHARMA LIMITED revenue for the last quarter amounts to ‪14.06 B‬ INR, despite the estimated figure of ‪14.26 B‬ INR. In the next quarter, revenue is expected to reach ‪15.72 B‬ INR.
GLAND net income for the last quarter is ‪1.64 B‬ INR, while the quarter before that showed ‪1.44 B‬ INR of net income which accounts for 13.75% change. Track more GLAND PHARMA LIMITED financial stats to get the full picture.
Yes, GLAND dividends are paid annually. The last dividend per share was 20.00 INR. As of today, Dividend Yield (TTM)% is 1.15%. Tracking GLAND PHARMA LIMITED dividends might help you take more informed decisions.
GLAND PHARMA LIMITED dividend yield was 1.09% in 2023, and payout ratio reached 42.64%. The year before the numbers were 0.00% and 0.00% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 30, 2024, the company has ‪4.22 K‬ employees. See our rating of the largest employees — is GLAND PHARMA LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GLAND PHARMA LIMITED EBITDA is ‪12.76 B‬ INR, and current EBITDA margin is 23.67%. See more stats in GLAND PHARMA LIMITED financial statements.
Like other stocks, GLAND shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GLAND PHARMA LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GLAND PHARMA LIMITED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GLAND PHARMA LIMITED stock shows the buy signal. See more of GLAND PHARMA LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.